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Fluorophores based on organic molecules hold great potential for ligand-targeted imaging 
applications, particularly those operating in the optical window in biological tissues. In this 
work we have developed three straightforward solid-phase approaches based on amide-bond 
formation or Cu(I)-catalyzed azide–alkyne click (CuAAC) reaction for labelling octreotide 
peptide with far-red emitting coumarin-based COUPY dyes. First, the conjugatable versions 
of COUPY fluorophores incorporating the required functional groups (e.g., carboxylic acid, 
azide or alkyne) were synthesized and characterized. All of them were found fully compatible 
with Fmoc/tBu solid-phase peptide synthesis, which allowed the labeling of octreotide either 
through amide-bond formation or by CuAAC reaction. A near quantitative conversion was 
obtained after only 1 h of reaction at RT when using CuSO4 and sodium ascorbate 
independently of the click chemistry approach used (azido-COUPY/alkynyl-peptide resin or 
alkynyl-COUPY/azido-peptide resin). COUPY-octreotide conjugates were found stable in 
cell culture medium as well as non-cytotoxic in HeLa cells, and their spectroscopic and 
photophysical properties were found similar to those of their parent coumarin dyes. Finally, 
the potential bioimaging applications of COUPY-octreotide conjugates were demonstrated by 
confocal microscopy through the visualization of living HeLa cells overexpressing 







Last few decades have witnessed an impressive growth in the development of novel 
therapeutic and diagnostic technologies against cancer. In this context, receptors over-
expressed on cancer cells have been exploited to selectively deliver a large variety of 
cytotoxic drugs with the aim of minimizing toxic side-effects associated with chemotherapy. 
Ligand-targeted imaging agents also offer great potential in the early detection of cancerous 
cells, as well as in fluorescence-guided surgery (FGS), which allows resection of solid 
tumours after illumination of malignancies directly in the operating room.
1
 Recent advances 
in fluorophore chemistry and knowledge of targetable receptors have led to the clinical testing 
of several targeted fluorophores for intraoperative cancer detection and FGS.
1b,2
 
Owing to the potential of fluorophores based on organic molecules in ligand-targeted imaging 
applications, it is urgent to develop novel low molecular-weight fluorescent probes operating 
in the far-red and near-infrared (NIR) region, since only the use of non-toxic and high tissue-
penetrating radiation will guarantee clinical translation in the next years.
3
 Ideally, such 
fluorophores should be amenable to smart structural modifications to tune, on demand, 
photophysical and physicochemical properties, as well as to facilitate conjugation to a broad 
variety of targeting ligands (e.g., peptides, proteins, folic acid, monoclonal antibodies (mAb), 
etc.) by using efficient and chemoselective conjugation chemistries. Although many times 
forgotten, the biological properties of a targeting ligand should not be impaired by the 
fluorescent tag. This issue is particularly problematic in the case of short peptide sequences 
since uptake and subcellular localization may be strongly influenced by the fluorophore.
4
 In 
the same way, some structural modifications of cyanine-based dyes have been reported to 
alter the mechanism of mAb when conjugated together, and non-specific hydrophobic 
interactions between Epidermal Growth Factor (EGF) receptor and the dye moiety in 
BODIPY-peptide conjugates were found to reduce peptide-receptor binding specificity.
5
 
Hence, the choice of the fluorophore cannot be underestimated since constitutes a critical 
parameter in ligand-targeted imaging applications. 
Recently, we have developed a novel family of coumarin-based fluorophores, nicknamed 
COUPYs, with promising photophysical properties and great potential for imaging 
applications.
6
 As shown in Figure 1, replacement of the carbonyl function in coumarin 1 with 
the cyano(4-pyridine)methylene moiety (e.g., compound 2) allowed us to increase the 
push−pull character of the conventional coumarin chromophore, which was easily 
transformed into pH-independent far-red/NIR-emitting fluorophores through N-alkylation of 
the pyridine heterocycle (e.g., compound 3). Although the photostability of COUPY dyes can 
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be tuned through the incorporation of CF3 groups at the coumarin skeleton
6
 or by replacement 
of N,N-dialkylamino groups at position 7 with the four membered ring azetidine,
6b
 the 
electron-withdrawing cyano group might also have a role in their photostability as previously 
demonstrated in some cyanine derivatives and in other dyes.
7
 Considering the small size and 
the easy synthetic accessibility to COUPY dyes, these compounds are potential candidates for 
labelling targeting ligands such as receptor-binding peptides. In such a context, we envisaged 
that conjugatable versions of COUPY dyes (e.g., compounds 4 to 6 in Figure 1) could be 
obtained from scaffold 2 through N-alkylation with adequate reagents, thereby providing 
suitable functional groups (e.g., carboxylic acid, azide or alkyne) for conjugation via amide-





Figure 1. Rational design of conjugatable versions of COUPY dyes (A) and schematic representation 
of COUPY-octreotide conjugates (B). 
 
Herein, we report for the first time three straightforward solid-phase approaches for the 
conjugation of coumarin-based COUPY fluorophores to octreotide, a FDA-approved peptide 
that displays high affinity and selectivity for somatostatin receptors, mainly subtype-2 
receptor (SSTR2) which is overexpressed on the membrane of various types of malignant 
cells.
9
 This cyclic octapeptide is a promising candidate for developing novel targeted imaging 





conjugates, are routinely used in the clinics for molecular imaging and therapy of 
neuroendocrine tumors, respectively, and several other SSTR2-targeted radiotherapeutics are 
currently under clinical evaluation.
1a
 Octreotide has also been conjugated successfully to 
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several anticancer drugs (both organic compounds and metallodrugs),
10
 including Ir(III) 








RESULTS AND DISCUSSION 
Synthesis and characterization of conjugatable COUPY dyes.  
COUPY fluorophores 4-6 were easily synthesized through N-alkylation of 2 (Scheme 1), 
which was previously obtained by condensation of thiocoumarin 7
6,12
 with 4-
pyridylacetonitrile. On the one hand, reaction of 2 with methyl bromoacetate afforded 
intermediate 8 in excellent yield after silica column chromatography (97%). This compound 
was transformed into coumarin 4 bearing the carboxylic acid function by acidic hydrolysis 
(Figure S1). On the other hand, azido- (5) and alkynyl- (6) containing fluorophores were 
synthesized by reaction of 2 with N-alkyl bromoacetamide derivatives containing the 
appropriate functional groups for CuAAC (compounds 9 and 10, respectively). Compounds 5 
and 6 were obtained as dark blue solids after purification (96% and 80% yields, respectively). 




C) and 2D NMR, and 
the purity was assessed by reversed-phase HPLC (Figure S1). Similarly to the parent COUPY 






Scheme 1. Synthesis of conjugatable COUPY dyes 4-6. 
 
Synthesis and characterization of COUPY-octreotide conjugates. 
Having at hand the conjugatable COUPY derivatives (4-6), we focused on labelling octreotide 
following a stepwise solid-phase strategy since it allows the regioselective attachment of the 
fluorescent dye at the N-terminal end of the peptide sequence, either through amide-bond 
formation or by Cu(I)-catalyzed click chemistry. First, the linear octapeptide sequence 
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incorporating a short polyethylenglycol spacer (11) was assembled manually on a Rink amide 
resin-p-MBHA using standard Fmoc-tBu methodology (Scheme 2). After coupling of 
coumarin 4 with HATU in the presence of DIPEA, side-chain deprotection and cleavage from 
the resin (TFA/TIS/H2O/EDT 94:2.5:2.5:1, 2.5 h RT) and cyclization via disulfide bond 
formation in an aqueous buffer (pH 7-8) were carried out. Analysis by HPLC-ESI MS showed 
a main peak (Figure S5) that was isolated and characterized as the expected COUPY-
octreotide conjugate (12). Finally, after purification by semipreparative HPLC and 
lyophilization, the formate salt of 12 (overall yield 12%) was obtained as a pink solid and 
fully characterized by HR ESI-MS and NMR. As shown in Figure S6, the obtained m/z values 







In addition, the aromatic region of the 
1
H NMR spectra in 8:2 H2O/D2O-DMSO-d6 mixtures 
showed diagnostic peaks from the fluorophore and the peptide (amide NH protons and 
aromatic protons of D/L-Phe and D-Trp residues), confirming the covalent attachment of both 
moieties (Figure 2). Importantly, conjugate 12 was found stable in cell culture medium 
(DMEM supplemented with 10 % FBS) after incubation for 24 h (Figure S7), as well as non-
cytotoxic in HeLa cells (Figure S8). Both pre-requisites are necessary for exploring the 
bioimaging applications of COUPY-peptide conjugates. 
 
 
Scheme 2. Schematic representation of the three solid-phase approaches used for labelling 







Figure 2. Aromatic region of the 
1
H NMR spectra of conjugate 12 in D2O-DMSO-d6 8:2 (top) 
and in H2O-DMSO-d6 8:2 (bottom). 
 
Once demonstrated the compatibility of COUPY dyes with solid-phase peptide synthesis 
(SPPS), we investigated the potential applications of coumarin derivatives bearing azide (5) 
and alkynyl (6) functional groups for labelling octreotide via CuAAC reaction on solid-phase, 
since click chemistry is routinely employed for modifying peptides, oligonucleotides, small 
molecules and polymers.
13
 First, the required functional groups were incorporated at the N-
terminal end of peptide-bound resin 11 by coupling 4-pentynoic acid or 2-azidoacetic acid, 
which provided alkynyl- (13) and azido- (14) peptide-bound resins, respectively, (Figures S9-
S10). Click chemistry was investigated by reacting 13 and 14 resins with 5 and 6, 
respectively, in the presence of CuSO4 (3 mol equiv.) and sodium ascorbate (3 mol equiv.) in 
DMF/H2O 20:1 for 18 h (Scheme 2). To our delight, after cleavage and deprotection, HPLC-
MS analysis revealed the formation of the expected linear COUPY-octreotide conjugates. 
Since no significant side reactions derived of the presence of sodium ascorbate and Cu(I) 
were detected, we decided not to explore the use of Cu-stabilizing ligands. Although most 
click chemistry procedures reported in the literature describe the use of long reaction times 
(12-48 h) and even microwave irradiation for labelling peptides with organic fluorophores,
13a
 
we obtained near quantitative conversions after only 1 h of reaction at RT (see Figures S11 
and S14 for the HPLC-MS analyses after 1 h, 4 h and overnight reaction times), 
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independently of the click chemistry approach used (azido-COUPY/alkynyl-peptide resin or 
alkynyl-COUPY/azido-peptide resin). Finally, after cyclization and purification, clicked 
COUPY-octreotide conjugates (15 and 16) were obtained as pink solids (Figures S13-S14 and 
S15-S16). 
 
Photophysical characterization of COUPY-octreotide conjugates. 
The photophysical properties (absorption and emission spectra, molar absorption coefficients 
(), and fluorescence quantum yields (F)) of COUPY-octreotide conjugates were studied in 
water and in PBS buffer, and compared with those of their respective coumarin precursors 
(see Table 1 and Figure 3 and Figures S17-S20). All the compounds showed an intense 
absorption band in the yellow-red part of the visible spectrum, being the wavelength 
absorption maximum slightly red-shifted with respect the parent dye 3 (e.g., abs = 543 nm for 
3 vs em = 555 nm for 5-6 and 8 in H2O) because of the additional electron-withdrawing effect 
of ester and amide functions. Similarly, the emission maximum was red-shifted by ca 10 nm 
(e.g., em = 605 nm for 3 vs em = 615 nm for 5-6 and 8 in H2O) and, consequently, the 
Stokes’s shifts remained around 60-62 nm. An additional red-shift in absorption (ca 4-6 nm) 
and emission (ca 3-5 nm) maxima occurred after conjugation to octreotide. As shown in 
Table 1, the F of the conjugatable coumarin derivatives (8 and 5-6) in aqueous media was 
reduced when compared with 3 (e.g., F = 0.066 for 5 vs F = 0.15 for 3 in H2O). However, a 
clear improvement in the fluorescent quantum yield of these fluorophores was achieved when 
conjugated to the peptide (e.g., F = 0.066 for 5 vs F = 0.19 for conjugate 15 in H2O), 
independently of the chemical conjugation approach used.  
 
Figure 3. Comparison of the normalized absorption (solid lines) and fluorescence emission 



























Table 1. Photophysical properties of COUPY dyes (3, 5, 6 and 8) and COUPY-octreotide 
conjugates (12, 15-16) in PBS buffer and in H2O. The data for coumarin derivative 3 has been 
included for comparison purposes.
6a 









PBS 543 603 60 34 0.14 
H2O 543 605 62 31 0.15 
Coumarin 8 
PBS 554 615 61 48 0.044 
H2O 555 615 60 48 0.043 
Coumarin 5 
PBS 554 616 62 47 0.063 
H2O 555 615 60 50 0.066 
Coumarin 6 
PBS 553 615 62 45 0.045 
H2O 555 615 60 46 0.061 
Conjugate 12 
PBS 561 620 59 24 0.14 
H2O 561 618 57 27 0.17 
Conjugate 15 
PBS 559 620 61 32 0.18 
H2O 560 618 58 36 0.19 
Conjugate 16 
PBS 559 618 59 26 0.14 
H2O 560 618 58 30 0.19 
 
Fluorescence imaging of COUPY-octreotide conjugates in living cells 
Finally, we investigated the potential bioimaging applications of COUPY-octreotide 
conjugates. As a representative compound, we selected conjugate 12 and studied its cellular 
uptake by confocal microscopy in SSTR2-overexpressing HeLa cells after irradiation with a 
yellow light laser (λex = 561 nm). Interestingly, fluorescent vesicles, mostly-like endosomes, 
were visible in the cytoplasm of all of the examined cells after 30 min of incubation with 12, 
thereby confirming the internalization and accumulation of COUPY-octreotide conjugate in 
the cells (Figures 4 and S23). This pattern of staining contrasts with that of coumarin 3 
(Figure S23), which accumulates preferentially in mitochondria and nucleoli,
6
 and indicates 
that the internalization of COUPY-octreotide conjugate is driven exclusively by the peptide 
moiety and not by the coumarin tag. In order to get more insights into the cellular uptake of 
the conjugate, we incubated HeLa cells with 12 at 4 
o
C for 30 min. As shown in Figure 5, no 
staining was observed inside the cytoplasm, which confirms that 12 enters the cells only 
through an energy-dependent pathway. By contrast, the pattern of staining observed with 3 
was not modified at low temperature (Figure 5), thereby suggesting internalization through 






Figure 4. Comparison of the cellular uptake of COUPY- (12), Atto Rho12- (17) and 
Fluorescein- (18) octreotide conjugates. Top: structures of the conjugates. Bottom: single 
confocal planes of HeLa cells incubated with 12 (A and D) and 17 (B and E) at 10 μM and 18 
(C and F) at 50 μM for 30 min at 37 
o
C. (A-C) Fluorescence images merged with bright field 
images. (D-F) Fluorescence images only. All fluorescence images are color coded using the 
Fire lookup table from Fiji. Scale bar: 20 μm. B,D,E same scale as A. F same scale as C.  
 
Next, we decided to compare the visualization ability of COUPY dyes when conjugated to 
octreotide with that of two common commercially available fluorophores: 5(6)-
carboxyfluorescein, which is one of the most popular fluorescent tags for labelling peptides 
and is typically excited at 488 nm, and Atto-Rho12, a rhodamine dye that can be excited with 
the same yellow light laser than our COUPY fluorophore. Atto-Rho12-octreotide (17) was 
synthesized by reaction of the corresponding succinimidyl ester derivative with octreotide and 
carboxyfluorescein-octreotide (18) was prepared by SPPS.
10b
 As shown in Figure 4, the 
performance of the COUPY dye when conjugated to octreotide was comparable to that of the 
12 
 
rhodamine dye when exciting at 561 nm under similar conditions. By contrast, COUPY 
fluorophore allowed a much better visualization of HeLa cells than carboxyfluorescein, even 
at much lower concentrations and with a more convenient excitation wavelength (561 nm vs 
488 nm). On the other hand, it is worth noting that conjugates involving carboxyfluorescein 
and Atto-Rho12 dyes (17 and 18) were obtained as regiomeric mixtures since both 
commercially available fluorophores are supplied as mixtures of isomers. However, COUPY-
octreotide conjugate 12 was easily obtained as a single product, which represents a suitable 
alternative to many conventional fluorophores when labeled biomolecules with a well-defined 
structure are required for biological applications. Moreover, it is important to note that the 
photostability of COUPY-octreotide conjugate (12) in PBS buffer under green light 
irradiation (505 ± 15 nm; Figure 6) was found similar to that of the parent coumarin 3,
6
 which 
indicates that peptide derivatization through the pyridine heterocycle does not significantly 
modify the photostability of COUPY dyes.   
 
Figure 5. Comparison of the cellular uptake of COUPY-octreotide conjugate 12 and COUPY 
dye 3. Single confocal planes of HeLa cells incubated with 12 (A and C) and 3 (B and D) at 
10 μM or 0.5 μM, respectively, first at 4 
o





for additional 30 min (C and D). The compounds were excited at 561 nm and emission 
detected from 570 to 670 nm. All images are color coded using the Fire lookup table from 
Fiji. Scale bar: 20 μm. 
 
 
Figure 6. Fluorescence bleaching of COUPY-octreotide conjugate 12 and COUPY dye 3 in 







In conclusion, we have synthesized three conjugatable versions of COUPY dyes (compounds 
4 to 6) incorporating suitable functional groups for conjugation via amide-bond formation 
(e.g., carboxylic acid) or copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) reaction 
(e.g., azide or alkyne). The compounds were easily obtained from a cheap, commercially 
available precursor, 7-N,N-diethylaminocoumarin, in only three or four linear steps, being the 
N-alkylation of the pyridine ring the key step. All the conjugatable coumarin derivatives were 
found fully compatible with Fmoc/tBu solid-phase peptide synthesis, which allowed the 
straightforward labeling of octreotide peptide with a far-red emitting fluorophore. On the one 
hand, attachment of the coumarin 4 bearing a carboxylic acid function to the N-terminal end 
of the linear peptide-bound resin followed by acidic cleavage and deprotection and cyclization 
led to the expected COUPY-octreotide conjugate (12). This conjugate was found stable in cell 
culture medium as well as non-cytotoxic in HeLa cells. On the other hand, clicked COUPY-
octreotide conjugates (15 and 16) were efficiently obtained by CuAAC reaction on solid-
phase between azide- (5) and alkynyl- (6) containing COUPY dyes and peptide-bound resins 
containing the complementary functional groups.  
The spectroscopic and photophysical properties of COUPY-octreotide conjugates were found 
similar to those of their parent coumarin dyes, being the wavelength absorption maximum 
located in the yellow-red part of the visible spectrum, while the emission ranged from the far 
red to the NIR region. Importantly, the fluorescent quantum yields of COUPY-octreotide 
conjugates in water were found higher than those of their coumarin precursors. Finally, the 
potential bioimaging applications of COUPY-octreotide conjugates were demonstrated by 
confocal microscopy in SSTR2-overexpressing living HeLa cells. Both the pattern of staining 
and the inhibition of the cellular uptake at low temperature indicate that the internalization of 
the conjugates is driven by the peptide moiety and not by the coumarin tag. Moreover, the fact 
that the visualization ability of COUPY dyes when conjugated to octreotide was similar to 
that of a commercially available rhodamine fluorophore, Atto-Rho12, and much better than 
that of the 5(6)-carboxyfluorescein, makes them as a suitable alternative when labeled 
biomolecules with a well-defined structure are required for biological applications. Work is in 
progress in our laboratory to increase the red-shifted properties of COUPY dyes with the aim 




Materials and Methods 
Unless otherwise stated, common chemicals and solvents (HPLC grade or reagent grade 
quality) were purchased from commercial sources and used without further purification. 
Fmoc-protected amino acids, resins, and coupling reagents for solid-phase synthesis were 
obtained from Novabiochem, Bachem, or Iris Biotech. Fmoc-L-threoninol p-carboxyacetal 
was synthesized following previously reported procedures.
14
 Solid-phase peptide synthesis 
(SPPS) was performed manually in a polypropylene syringe fitted with a polyethylene disk. 
Peptides were assembled on a Rink amide resin-p-MBHA (f = 0.50 mmol/g, 100−200 mesh) 
using standard Fmoc/
t
Bu chemistry with the following side-chain protecting groups: Boc (N
i
-





threonine), and Trt (S-trityl, cysteine).  
Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F254 were used for thin-
layer chromatography analyses (TLC), whereas flash column chromatography purification 
was carried out using silica gel 60 (230-400 mesh). Reversed-phase high-performance liquid 
chromatography (HPLC) analyses were carried out on a Jupiter Proteo C18 column (250x4.6 
mm, 90 Å 4 m, flow rate: 1 mL/min) using linear gradients of 0.1% formic acid in H2O (A) 
and 0.1% formic acid in ACN (B). NMR spectra were recorded at 25 
o
C in a 400 MHz 
spectrometer using the deuterated solvent as an internal deuterium lock. Tetramethylsilane 
(TMS) was used as an internal reference (0 ppm) for 
1
H spectra recorded in CDCl3 and the 
residual protic signal of the solvent (77.16 ppm) for 
13
C spectra. The residual protic signal of 




C NMR spectra recorded in DMSO-d6. Chemical 
shifts are reported in part per million (ppm) in the  scale, coupling constants in Hz and 
multiplicity as follows: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintuplet), m 
(multiplet), dd (doublet of doublets), dt (doublet of triplets), ddd (doublet of doublet of 
doublets), br (broad signal), etc. The proton signals of the E and Z rotamers were identified by 
simple inspection of the 
1
H spectrum and the rotamer ratio was calculated by peak integration. 
2D-NOESY spectra were acquired in DMSO-d6 with a mixing time of 500 ms. Electrospray 
ionization mass spectra (ESI-MS) were recorded on an instrument equipped with single 







Synthesis of compounds 9 and 10. 
N-(3-Azidopropyl)-2-bromoacetamide (9). The published method with some modifications 
was followed to synthesize compound 9.
15 
3-Azido-1-propanamine (250 mg, 2.5 mmol) was 
dissolved in 10 mL of DCM and then 10 mL of saturated aqueous NaHCO3 were added. The 
mixture was vigorously stirred at -10 ºC and bromoacetyl bromide (1.01 g, 5.0 mmol) was 
slowly added. The reaction mixture was slowly allowed to warm to room temperature. After 
stirring for 3 h, the reaction mixture was partially concentrated to remove the organic solvent 
and then poured into 100 mL of water. The aqueous phase was extracted with AcOEt (2 x 100 
mL), and the combined organic phases were washed with saturated NaHCO3 (100 mL), 5 % 
aqueous HCl solution (100 mL) and saturated NaCl (100 mL). The organic phase was dried 
over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product 
was purified by column chromatography (silica gel, 0-60 % AcOEt in hexane) to give 364 mg 
of a pink oil (yield: 66 %). TLC: Rf (hexane/DCM 1:1) 0.5. 
1
H NMR (400 MHz, CDCl3) δ 





(101 MHz, CDCl3) δ (ppm): 165.9, 49.3, 37.9, 29.1, 28.5. HRMS (ESI-TOF) m/z: [M + H]
+
 
Calcd for C5H10BrN4O 221.0033; Found 221.0027. MS (EI) m/z 220 (M
+
, 5), 178 (10), 141 










2-Bromo-N-(prop-2-yn-1-yl)acetamide (10). The published method with some modifications 
was followed to synthesize compound 10.
16 
Propargylamine (500 mg, 9.1 mmol) was 
dissolved in 20 mL of DCM and then 20 mL of saturated aqueous NaHCO3 were added. The 
mixture was vigorously stirred at -10 ºC and bromoacetyl bromide (3.66 g, 18.2 mmol) was 
slowly added. The reaction mixture was slowly allowed to warm to room temperature. After 
stirring for 3 h, the reaction mixture was partially concentrated to remove the organic solvent 
and then poured into 100 mL of water. The aqueous phase was extracted with AcOEt (2 x 100 
mL), and the combined organic phases were washed with saturated NaHCO3 (100 mL), 5 % 
aqueous HCl solution (100 mL) and saturated NaCl (100 mL). The organic phase was dried 
over anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude product 
was purified by column chromatography (silica gel, 0-60 % AcOEt in hexane) to give 0.87 g 
of a white solid (yield: 55 %). TLC: Rf (hexane/DCM 1:1) 0.5. 
1
H NMR (400 MHz, CDCl3) δ 
(ppm): 6.60 (1H, br s), 3.85 (2H, s), 4.09 (2H, dd, J = 5.6 Hz, J = 2.4 Hz), 3.90 (2H, s), 2.28 




H} NMR (101 MHz, CDCl3) δ (ppm): 165.2, 78.6, 72.4, 30.1, 28.8. 
HRMS (ESI-TOF) m/z: [M + H]
+















Synthesis of coumarin derivatives (4-6 and 8).  
2-(Cyano(1-(2-methoxy-(2-oxoethyl))(4-pyridin-1-ium))methylene)-7-(N,N-diethylamino)-4-
methyl-coumarin bromide (8). Methyl bromoacetate (140 µL, 1.51 mmol) was added to a 
solution of coumarin 2
6a
 (500 mg, 1.51 mmol) in AcOEt (60 mL). The mixture was stirred for 
4 h at 60 ºC under an Ar atmosphere and protected from light. Then, methyl bromoacetate 
(140 µL, 1.51 mmol) was added again and the reaction mixture was stirred overnight at 60 ºC 
and protected from light. The crude product was evaporated under reduced pressure and 
purified by column chromatography (silica gel, 0-8% MeOH in DCM) to give 713 mg of 
purple solid (yield: 97 %). TLC: Rf (10% MeOH in DCM) 0.55. 
1
H NMR (400 MHz, DMSO-
d6) δ (ppm): 8.59 (2H, d, J = 7.2 Hz), 8.17 (2H, d, J = 7.2 Hz), 7.70 (1H, d, J = 9.0 Hz), 7.04 
(1H, d, J = 2.0 Hz), 6.96 (1H, dd, J = 9.0 Hz, J = 2.8 Hz), 6.89 (1H, s), 5.51 (2H, s), 3.78 (3H, 




H} NMR (101 MHz, 
DMSO-d6) δ (ppm): 167.6, 166.8, 154.9, 153.2, 152.1, 149.6, 144.0, 127.0, 120.1, 118.0, 
112.1, 110.4, 96.5, 78.2, 58.3, 53.0, 44.2, 18.5, 12.4. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for 
C24H26N3O3 404.1969; Found 404.1963. Analytical HPLC (30 to 100% B in 30 min, formic 
acid additive): Rt = 7.3 min 
2-(Cyano(1-(carboxymethyl)(4-pyridin-1-ium))methylene)-7-(N,N-diethylamino)-4-methyl-
coumarin chloride (4). A 1:1 (v/v) mixture of HCl (37 %) and Milli-Q water (170 mL) was 
added to coumarin 8 (500 mg, 1.03 mmol). The reaction mixture was stirred for 5 h at 60 ºC 
under an Ar atmosphere and protected from light. After removal of the major part of the 
solvent, several co-evaporations from acetonitrile were carried out. The crude product was 
used without further purification since HPLC-MS analysis revealed that the hydrolysis 
reaction was quantitative. 
1
H NMR (400 MHz, DMSO-d6) δ (ppm): 8.59 (2H, d, J = 7.4 Hz), 
8.18 (2H, d, J = 7.4 Hz), 7.72 (1H, d, J = 9.2 Hz), 7.04 (1H, br s), 6.98 (1H, dd, J = 9.2 Hz, J 
= 2.4 Hz), 6.93 (1H, d, J=2.4 Hz), 5.39 (2H, s), 3.56 (4H, q, J = 7.2 Hz), 2.55 (3H, s), 1.18 
(6H, t, J = 7.2 Hz). HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C23H24N3O3 390.1812; Found 
390.1808. Analytical HPLC (30 to 100% B in 30 min, formic acid additive): Rt = 10.2 min). 
2-(Cyano(1-(2-((3-azidopropyl)amino)-2-oxoethyl))(4-pyridin-1-ium))methylene)-7-(N,N-
diethylamino)-4-methyl-coumarin bromide (5). N-(3-Azidopropyl)-2-bromoacetamide (167 
mg, 0.75 mmol) was added to a solution of coumarin 2
6a
 (250 mg, 0.75 mmol) in a 1:1 
mixture of AcOEt and ACN (30 mL), which was previously heated at 50 ºC. After stirring for 
2 h at 50 ºC, an additional amount of compound 9 (167 mg, 0.75 mmol) was added and the 
18 
 
reaction mixture was stirred for 5 h at 50 ºC. After evaporation under reduced pressure and 
purification by column chromatography (silica gel, 0-6% MeOH in DCM), 400 mg of a dark 
purple solid were obtained (yield: 96 %). TLC: Rf (10% MeOH in DCM) 0.45. 
1
H NMR (400 
MHz, DMSO-d6) δ (ppm): 8.58 (1H, t, J = 5.6 Hz), 8.53 (2H, d, J = 7.4 Hz), 8.16 (2H, d, J = 
7.4 Hz), 7.72 (1H, d, J = 9.2 Hz), 7.01 (1H, br s), 6.98 (1H, dd, J = 9.2 Hz, J = 2.4 Hz), 6.93 
(1H, s), 5.24 (2H, s), 3.56 (4H, q, J = 7.2 Hz), 3.41 (2H, t, J = 6.8 Hz), 3.21 (2H, q, J = 6.8 




H} NMR (101 
MHz, DMSO-d6) δ (ppm): 166.8, 165.0, 154.9, 152.8, 152.0, 149.2, 144.2, 127.0, 120.0, 
118.2, 111.9, 110.4, 96.4, 78.1, 59.5, 54.9, 48.2, 44.2, 36.3, 28.2, 18.4, 12.3. HRMS (ESI-
TOF) m/z: [M]
+
 Calcd for C26H30N7O2 472.2455; Found 472.2450. Analytical HPLC (30 to 
100% B in 30 min, formic acid additive): Rt = 8.0 min. 
2-(Cyano(1-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl))(4-pyridin-1-ium))methylene)-7-(N,N-
diethylamino)-4-methyl-coumarin bromide (6). 2-Bromo-N-(prop-2-yn-1-yl)acetamide (10) 
(42 mg, 0.75 mmol) was added to a solution of coumarin 2
6a
 (250 mg, 0.75 mmol) in a 1:1 
mixture of AcOEt and ACN (30 mL), which was previously heated at 50 ºC. After stirring for 
2 h at 50 ºC, an additional amount of compound 9 (63 mg, 1.12 mmol) was added and the 
reaction mixture was stirred overnight at 50 ºC. After evaporation under reduced pressure and 
purification by column chromatography (silica gel, 0-6% MeOH in DCM), 304 mg of a dark 
purple solid were obtained (yield: 80 %). TLC: Rf (10% MeOH in DCM) 0.60. 
1
H NMR (400 
MHz, DMSO-d6) δ (ppm): 9.01 (1H, t, J = 5.6 Hz), 8.53 (2H, d, J = 7.4 Hz), 8.16 (2H, d, J = 
7.4 Hz), 7.72 (1H, d, J = 9.2 Hz), 7.01 (1H, br s), 6.98 (1H, dd, J = 9.2 Hz, J = 2.4 Hz), 6.93 
(1H, s), 5.27 (2H, s), 3.98 (2H, dd, J = 5.6 Hz, J = 2.4 Hz), 3.57 (4H, q, J = 7.2 Hz), 3.23 (1H, 




H} NMR (101 MHz, DMSO-d6) δ 
(ppm): 166.8, 165.0, 154.9, 152.9, 152.0, 149.3, 144.2, 127.0, 120.0, 118.2, 111.9, 110.5, 
110.4, 96.4, 80.3, 78.1, 73.8, 59.3, 44.2, 28.4, 18.4, 12.4. HRMS (ESI-TOF) m/z: [M]
+
 Calcd 
for C26H27N4O2 427.2129; Found 427.2127. Analytical HPLC (30 to 100% B in 30 min, 
formic acid additive): Rt = 7.3 min. 
Synthesis and characterization of COUPY-octreotide conjugate 12 
Fmoc-NH-PEG-D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)-Resin 
(11). Octreotide-bound resin 11 was prepared following previously reported procedures.
9b
 
Briefly, the Fmoc-protected L-threoninol functionalized as the p-carboxybenzaldehyde acetal 
was anchored to the solid support by using DIPC (3 mol equiv) and HOBt (3 mol equiv) in 
anhydrous DMF for 3 h and, subsequently, the following Fmoc-protected amino acids as well 
as the Fmoc-protected PEG spacer, 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-
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dioxaoctanoic acid, were incorporated using DIPC (3 mol equiv) and HOAt (3 mol equiv) in 
anhydrous DMF for 2 h.  
COUPY-octreotide conjugate (12). After removal of the Fmoc protecting group from peptide-
bound resin 11 with 20 % piperidine in DMF (2 x 10 min), coumarin 4 (4 mol equiv.) was 
coupled by using HATU (3.9 mol equiv.) and DIPEA (2+2 mol equiv.) in anhydrous DMF for 
3 h in the dark by using the following procedure: DIPEA (2 mol equiv.) was first added to a 
solution of coumarin 4 and HATU in anhydrous DMF and, after stirring for 5 min a RT, the 
mixture was added to DMF-swollen peptide-bound resin 11; then, DIPEA (2 mol equiv.) was 
immediately added and the reaction mixture was stirred for 2 h. Cleavage and deprotection of 
the resulting COUPY-octreotide-bound resin were simultaneously performed by treatment 
with TFA/H2O/EDT/TIS 94:2.5:2.5:1 for 2.5 h at RT and protected from light. Most of the 
TFA was removed by bubbling N2 into the solution, and the resulting residue was poured onto 
cold diethyl ether to precipitate the target compound. The solid was isolated by centrifugation, 
dissolved in H2O/ACN (9:1) and lyophilized. Cyclisation was accomplished after 
continuously stirring an aerated solution of the crude material in a 97:3 (v/v) mixture of 
aqueous NH4HCO3 (5%) pH 7-8 and DMSO overnight at RT (1 mL solution per 1 mg of 
theoretical peptide). As shown in Figure S5, analytical reversed-phase HPLC-MS analysis (10 
to 70% B in 30 min, 0.1 % formic acid additive) revealed the presence of a main peak that 
was characterized as the expected COUPY-octreotide conjugate 12 (Rt = 15.6 min). The 
solution was lyophilized and the conjugate purified by semipreparative RP-HPLC (gradient 
from 45 to 70% B in 30 min, A: 0.045 % TFA in H2O, B: 0.1% TFA in ACN, flow rate: 3 
mL/min, Rt = 6 min). Overall yield (synthesis + purification): 2.35 mg of a purple solid (from 
27 mg of resin 11), 12%. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C78H99N14O15S2 1535.6850; 
Found 1535.6844; m/z: [M + H]
2+
 Calcd for C78H100N14O15S2 768.3462; Found 768.3469. 
Analytical RP-HPLC (10 to 70% B in 30 min; A, 0.1% formic acid in H2O; B, 0.1% formic 
acid in ACN; Rt = 15.6 min). 
Synthesis and characterization of COUPY-octreotide conjugates 15 and 16 
Alkynyl-PEG-D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)-Resin 
(13). After removal of the Fmoc protecting group from the peptide-bound resin 11 with 20 % 
piperidine in DMF (2 x 10 min), 4-pentynoic acid (5 mol equiv.) was coupled by using DIPC 
(5 mol equiv.) and HOAt (5 mol equiv.) in anhydrous DMF for 2 h. Cleavage and 
deprotection of an aliquot of the resulting octreotide-bound resin 13 was performed by 
treatment with TFA/H2O/EDT/TIS 94:2.5:2.5:1 for 2.5 h. After evaporation of TFA by 
bubbling with N2, the crude peptide was precipitated with cold diethyl ether. As shown in 
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Figure S9, reversed-phase HPLC-MS analysis showed the presence of two peaks that were 
characterized as the linear alkynyl-octreotide (Rt = 15.2 min) and the corresponding disulfide 
cyclized alkynyl-octreotide (Rt = 14.8 min). Linear alkynyl-octreotide: LR-ESI MS, positive 
mode: m/z 1246.54 (calcd mass for C60H84N11O14S2 [M+H]
+
: 1246.56). Analytical HPLC (10 
to 70% B in 30 min, 0.1 % formic acid additive): Rt = 15.2 min. Disulfide cyclized alkynyl-
octreotide: LR-ESI MS, positive mode: m/z 1244.71 (calcd mass for C60H82N11O14S2 [M+H]
+
: 
1244.55). Analytical HPLC (10 to 70% B in 30 min, 0.1 % formic acid additive): Rt = 14.7 
min.   
Azido-PEG-D-Phe-Cys(Trt)-Phe-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(ol)-Resin (14). 
After removal of the Fmoc protecting group from the peptide-bound resin 11 with 20 % 
piperidine in DMF (2 x 10 min), 2-azidoacetic acid (5 mol equiv.) was coupled by using 
DIPC (5 mol equiv.) and HOAt (5 mol equiv.) in anhydrous DMF for 2 h. Cleavage and 
deprotection of an aliquot of the resulting octreotide-bound resin 14 was performed by 
treatment with TFA/H2O/EDT/TIS 94:2.5:2.5:1 for 2.5 h. After evaporation of TFA by 
bubbling with N2, the crude peptide was precipitated with cold diethyl ether. As shown in 
Figure S10, reversed-phase HPLC-MS analysis showed the presence of two peaks that were 
characterized as the linear azido-octreotide (Rt = 15.2 min) and the corresponding disulfide 
cyclized azido-octreotide (Rt = 14.7 min). Linear azido-octreotide: LR-ESI MS, positive 
mode: m/z 1249.50 (calcd mass for C57H81N14O4S2 [M+H]
+
: 1249.55). Analytical HPLC (10 
to 70% B in 30 min, 0.1 % formic acid additive): Rt = 15.2 min. Disulfide cyclized azido-
octreotide: LR-ESI MS, positive mode: m/z 1247.48 (calcd mass for C57H79N14O4S2 [M+H]
+
: 
1247.53). Analytical HPLC (10 to 70% B in 30 min, 0.1 % formic acid additive): Rt = 14.7 
min.   
COUPY-octreotide conjugate (15). 5 mg of alkynyl-peptide-bound resin 13 were transferred 
to a 2 mL reaction vial equipped with a magnetic stirrer. Afterwards, a solution of azido-
coumarin 5 (4.2 mg, 3 mol equiv.), CuSO4 (1.2 mg, 3 mol equiv.) and sodium ascorbate (1.5 
mg, 3 mol equiv.) in 800 µL DMF/H20 20:1 (v/v) was immediately added to the vial. The 
suspension was allowed to stir at room temperature for 1 h, 4 h or overnight under argon 
atmosphere in the dark. Then, the resin was filtered off and washed with DMF, DCM and 
MeOH (5,5,5 x 4 mL). Cleavage, deprotection and cyclisation were carried out as described 
above for conjugate 12. As shown in Figure S9, analytical reversed-phase HPLC-MS analysis 
(10 to 70% B in 30 min, 0.1 % formic acid additive) revealed the presence of a main peak in 
the three cases that was characterized as the expected COUPY-octreotide conjugate 15 (Rt = 
15.4 min). The solution was lyophilized and the conjugate purified by semipreparative RP-
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HPLC (gradient from 45 to 100% B in 30 min, A: 0.1 % TFA in H2O, B: 0.1% TFA in ACN, 
flow rate: 3 mL/min, Rt = 6.5 min). Overall yield (synthesis + purification): 5.23 mg of a 
purple solid (from 15 mg of resin 13), 32%. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for 
C86H111N18O16S2 1715.7861; Found 1715.7912; m/z: [M + H]
2+
 Calcd for C86H112N18O16S2 
858.3970; Found 858.3973. Analytical RP-HPLC (10 to 70% B in 30 min; A, 0.1% formic 
acid in H2O; B, 0.1% formic acid in CAN): Rt = 15.4 min. 
COUPY-octreotide conjugate (16). 5 mg of azido-peptide-bound resin 14 were transferred to 
a 2 mL reaction vial equipped with a magnetic stirrer. Afterwards, a solution of alkynyl-
coumarin 6 (3.8 mg, 3 mol equiv.), CuSO4.(1.2 mg, 3 mol equiv.) and sodium ascorbate (1.5 
mg, 3 mol equiv.) in 800 µL DMF/H20 20:1 (v/v) was immediately added to the vial. The 
suspension was allowed to stir at room temperature for 1 h, 4 h or overnight under argon 
atmosphere in the dark. Then, the resin was filtered off and washed with DMF, DCM and 
MeOH (5,5,5 x 4 mL). Cleavage, deprotection and cyclisation were carried out as described 
above for conjugate 12. As shown in Figure S11, analytical reversed-phase HPLC-MS 
analysis (10 to 70% B in 30 min, 0.1 % formic acid additive) revealed the presence of a main 
peak in the three cases that was characterized as the expected COUPY-octreotide conjugate 
16 (Rt = 15.3 min). The solution was lyophilized and the conjugate purified by 
semipreparative RP-HPLC (gradient from 45 to 100% B in 30 min, A: 0.1 % TFA in H2O, B: 
0.1% TFA in ACN, flow rate: 3 mL/min, Rt = 6.5 min). Overall yield (synthesis + 
purification): 5.23 mg of a purple solid (from 20 mg of resin 14), 13%. HRMS (ESI-TOF) 
m/z: [M]
+
 Calcd for C83H105N18O16S2 1673.7392; Found 1673.7388; m/z: [M + H]
2+
 Calcd for 
C83H106N18O16S2 837.3750; Found 837.3735. Analytical RP-HPLC (10 to 70% B in 30 min; 
A, 0.1% formic acid in H2O; B, 0.1% formic acid in ACN): Rt = 15.3 min. 
Synthesis and characterization of Atto-Rho12-octreotide conjugate (17).  
Octreotide acetate (Bachem; 1 mg, 0.98 µmol) was allowed to react with Atto Rho12-
hexanoic acid N-hydroxysuccinimide ester (ATTO Tech; 1 mg, 1.18 µmol) in an aqueous 
hydrogencarbonate buffer (100 mM, pH 7.5) for 3 h and protected from light. The solution 
was lyophilized and Atto-Rho12-octreotide conjugate (17) was purified by analytical RP-
HPLC (gradient from 30 to 100 % in 30 min; A: 0.1 % formic acid in H2O, B: 0.1% formic 
acid in ACN, flow rate: 1 mL/min, Rt = 16.7 min). Overall yield (synthesis + purification): 0.4 








Photophysical characterization of the compounds. 
Absorption spectra were recorded in a Varian Cary 500 UV/Vis/NIR spectrophotometer at 
room temperature. Molar absorption coefficients () were determined by direct application of 





 M. Emission spectra were registered in a Photon Technology 
International (PTI) fluorimeter. Fluorescence quantum yields (ΦF) were measured by 
comparative method using cresyl violet in ethanol (CV; F;Ref = 0.54 ± 0.03) as reference.
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Then, optically-matched solutions of the compounds and CV were excited and the 
fluorescence spectra was recorded. The absorbance of sample and reference solutions was set 










𝑥 ф𝐹;𝑟𝑒𝑓  (1) 
where AreaSample and AreaRef are the integrated fluorescence for the sample and the reference 
and ƞSample and ƞRef are the refractive index of sample and reference solutions respectively. 
The uncertainty in the experimental value of F has been estimated to be approximately 10%. 
Photostability studies were performed by monitoring fluorescence bleaching of a 5 M 




Cell culture and treatments 
HeLa Cells were maintained in DMEM (Dullbecco Modified Eagle Medium) containing low 
glucose (1 g/L) and supplemented with 10% foetal calf serum (FCS), 50U/mL penicillin-
streptomycin and 2 mM L-glutamine. For cellular uptake experiments and posterior 
observation under the microscope, cells were seeded on glass bottom dishes (P35G-1.5-14-C, 
Mattek). 24 h after cell seeding, cells were incubated for 30 min or 1 h at 37 ºC with coumarin 
3 (0.5 M), COUPY-octreotide 12 (10 M), Atto Rho12-octreotide 17 (10 M) or 
Fluorescein-octreotide 18 (50 M) in supplemented DMEM. Then, cells were washed three 
times with DPBS (Dulbecco's Phosphate-Buffered Saline) to remove the excess of the 
compounds and kept in low glucose DMEM without phenol red for fluorescence imaging.  
Fluorescence imaging 
All microscopy observations were performed using a Zeiss LSM 880 confocal microscope 
equipped with a 405 nm laser diode, an Argon-ion laser, a 561 nm laser and a 633 nm laser. 
The microscope was also equipped with a full enclosure imaging chamber (XLmulti S1, 
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Pecon) connected to a 37 ºC heater and a 5% CO2 providing system. Cells were observed 
using a 63X 1.2 multi immersion objective. Compounds 3, 12 and 17 were excited using the 
561 nm laser and detected from 570 to 670 nm. Compound 18 was observed using the 488 nm 
laser line of the Argon-ion laser. Image analysis was performed using Fiji.
18
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